A large and ambitious study to handle the most common causes of death.
The estrogen-plus-progestin hormone therapy trial for ladies with their uteruses intact was stopped in July 2002 after investigators found that the associated health risks of the mixture hormone therapy outweighed the benefits. Less than 2 yrs later, in March 2004, NIH announced that it acquired stopped another part of the WHI, the estrogen-alone hormone therapy research for women who’ve got a hysterectomy, in the curiosity of safety after consideration of preliminary data and an average follow-up of almost seven years.This novel compound will reinforce Abbott’s immunology pipeline and we look forward to continuing to build on our experience in exploring multiple mechanisms and approaches to treat inflammatory diseases. Biotest is pleased to continue the development of BT-061 as well as Abbott, one of the globe leaders in the development and commercialization of biologic medicines for the treating immunological diseases, emphasized Prof. Dr. Gregor Schulz, CEO of Biotest AG. Using its tremendous experience in the field and its own global commercial strength and presence, Abbott may be the perfect partner for maximizing the commercial and therapeutic potential of BT-061.